Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...
Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
The SMC issued a green light for use by NHS Scotland of Roche’s Perjeta (pertuzumab) as an adjuvant (post-surgery) treatment to prevent relapse in patients with HER2-positive early-stage breast ...